Cargando…
Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis
Major advances have recently been made in the development and application of CFTR (cystic fibrosis transmembrane conductance regulator) mutation class-specific modulator therapies, but to date, there are no approved modulators for Class I mutations, i.e., those introducing a premature termination co...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621375/ https://www.ncbi.nlm.nih.gov/pubmed/34828417 http://dx.doi.org/10.3390/genes12111810 |
_version_ | 1784605442644639744 |
---|---|
author | Clarke, Luka A. Luz, Vanessa C. C. Targowski, Szymon Ramalho, Sofia S. Farinha, Carlos M. Amaral, Margarida D. |
author_facet | Clarke, Luka A. Luz, Vanessa C. C. Targowski, Szymon Ramalho, Sofia S. Farinha, Carlos M. Amaral, Margarida D. |
author_sort | Clarke, Luka A. |
collection | PubMed |
description | Major advances have recently been made in the development and application of CFTR (cystic fibrosis transmembrane conductance regulator) mutation class-specific modulator therapies, but to date, there are no approved modulators for Class I mutations, i.e., those introducing a premature termination codon (PTC) into the CFTR mRNA. Such mutations induce nonsense-mediated decay (NMD), a cellular quality control mechanism that reduces the quantity of PTC bearing mRNAs, presumably to avoid translation of potentially deleterious truncated CFTR proteins. The NMD-mediated reduction of PTC-CFTR mRNA molecules reduces the efficacy of one of the most promising approaches to treatment of such mutations, namely, PTC readthrough therapy, using molecules that induce the incorporation of near-cognate amino acids at the PTC codon, thereby enabling translation of a full-length protein. In this study, we measure the effect of three different PTC mutations on the abundance, integrity, and stability of respective CFTR mRNAs, using CFTR specific RT-qPCR-based assays. Altogether, our data suggest that optimized rescue of PTC mutations has to take into account (1) the different steady-state levels of the CFTR mRNA associated with each specific PTC mutation; (2) differences in abundance between the 3′ and 5′ regions of CFTR mRNA, even following PTC readthrough or NMD inhibition; and (3) variable effects on CFTR mRNA stability for each specific PTC mutation. |
format | Online Article Text |
id | pubmed-8621375 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86213752021-11-27 Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis Clarke, Luka A. Luz, Vanessa C. C. Targowski, Szymon Ramalho, Sofia S. Farinha, Carlos M. Amaral, Margarida D. Genes (Basel) Article Major advances have recently been made in the development and application of CFTR (cystic fibrosis transmembrane conductance regulator) mutation class-specific modulator therapies, but to date, there are no approved modulators for Class I mutations, i.e., those introducing a premature termination codon (PTC) into the CFTR mRNA. Such mutations induce nonsense-mediated decay (NMD), a cellular quality control mechanism that reduces the quantity of PTC bearing mRNAs, presumably to avoid translation of potentially deleterious truncated CFTR proteins. The NMD-mediated reduction of PTC-CFTR mRNA molecules reduces the efficacy of one of the most promising approaches to treatment of such mutations, namely, PTC readthrough therapy, using molecules that induce the incorporation of near-cognate amino acids at the PTC codon, thereby enabling translation of a full-length protein. In this study, we measure the effect of three different PTC mutations on the abundance, integrity, and stability of respective CFTR mRNAs, using CFTR specific RT-qPCR-based assays. Altogether, our data suggest that optimized rescue of PTC mutations has to take into account (1) the different steady-state levels of the CFTR mRNA associated with each specific PTC mutation; (2) differences in abundance between the 3′ and 5′ regions of CFTR mRNA, even following PTC readthrough or NMD inhibition; and (3) variable effects on CFTR mRNA stability for each specific PTC mutation. MDPI 2021-11-18 /pmc/articles/PMC8621375/ /pubmed/34828417 http://dx.doi.org/10.3390/genes12111810 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Clarke, Luka A. Luz, Vanessa C. C. Targowski, Szymon Ramalho, Sofia S. Farinha, Carlos M. Amaral, Margarida D. Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis |
title | Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis |
title_full | Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis |
title_fullStr | Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis |
title_full_unstemmed | Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis |
title_short | Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis |
title_sort | integrity and stability of ptc bearing cftr mrna and relevance to future modulator therapies in cystic fibrosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621375/ https://www.ncbi.nlm.nih.gov/pubmed/34828417 http://dx.doi.org/10.3390/genes12111810 |
work_keys_str_mv | AT clarkelukaa integrityandstabilityofptcbearingcftrmrnaandrelevancetofuturemodulatortherapiesincysticfibrosis AT luzvanessacc integrityandstabilityofptcbearingcftrmrnaandrelevancetofuturemodulatortherapiesincysticfibrosis AT targowskiszymon integrityandstabilityofptcbearingcftrmrnaandrelevancetofuturemodulatortherapiesincysticfibrosis AT ramalhosofias integrityandstabilityofptcbearingcftrmrnaandrelevancetofuturemodulatortherapiesincysticfibrosis AT farinhacarlosm integrityandstabilityofptcbearingcftrmrnaandrelevancetofuturemodulatortherapiesincysticfibrosis AT amaralmargaridad integrityandstabilityofptcbearingcftrmrnaandrelevancetofuturemodulatortherapiesincysticfibrosis |